Effects of Hedan Tablet () on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study.

Rui-xia XU; Na-qiong WU; Sha LI; Yan Zhang; Xiao-lin LI; Yuan-lin Guo; Cheng-gang Zhu; Geng Liu; Qian Dong; Jian-jun LI

Return

Effects of Hedan Tablet () on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study.

Author: Rui-Xia XU ¹ ; Na-Qiong WU ¹ ; Sha LI ¹ ; Yan ZHANG ¹ ; Xiao-Lin LI ¹ ; Yuan-Lin GUO ¹ ; Cheng-Gang ZHU ¹ ; Geng LIU ¹ ; Qian DONG ¹ ; Jian-Jun LI ²
Author Information

1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
2. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. lijianjun938@yahoo.com.
Publication Type:Journal Article
Keywords: Chinese medicine; Hedan Tablet; high-density lipoprotein subfraction; hyperlipidemia; lipid profile; proprotein convertase subtilisin/kexin type 9
MeSH: Drugs, Chinese Herbal; therapeutic use; Female; Humans; Hyperlipidemias; blood; drug therapy; enzymology; Lipoproteins, HDL; blood; Male; Middle Aged; Proprotein Convertase 9; metabolism; Subcellular Fractions; metabolism
From: Chinese journal of integrative medicine 2016;22(9):660-665
CountryChina
Language:English
Abstract:
OBJECTIVETo investigate the effects of Hedan Tablet () on serum lipid profile, proprotein convertase subtilisin/kexin type 9 (PSCK9) and high-density lipoprotein (HDL) subfractions in patients with hyperlipidemia.
METHODSThirty-seven patients with hyperlipidemia were randomized to treatment with Hedan Tablet 4.38 g/day as Hedan group (18 cases) or placebo (19 cases) as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups respectively.
RESULTSHedan treatment for 8 weeks mildly decreased serum low-density lipoprotein cholesterol (LDL-C) levels, while no changes were found in total cholesterol (TC), triglycerides (TG) and PCSK9 concentrations. Furthermore, Hedan treatment increased the concentration of large high-density lipoprotein cholesterol (HDL-C) and the percentage of large HDL subfraction, while decreased the concentration of small HDL-C and the percentage of small HDL subfraction without changing serum HDL-C levels in patients with hyperlipidemia.
CONCLUSIONHedan treatment of 4.38 g per day for 8 weeks could confer a favorable effects on serum LDL-C concentration as well as HDL subfractions.